In 2023, there were just seven confirmed cases of Zika virus in the United States, all of which were travel-associated. This is a huge decrease from 2016 when an outbreak of Zika resulted in over 5,000 cases in the United States and thousands more in South America, especially in Brazil. Zika virus can be transmitted through mosquito bites, from a pregnant woman to her fetus, through sex, and likely through blood transfusion. The Zika virus in the United States At the height of the latest Zika outbreak in the United States in 2016, almost every U.S. state reported cases of Zika virus infection, with the states of Florida and New York reporting the highest numbers with each over 1,000 cases. However, the vast majority of those cases were travel associated. Although most people with Zika virus only have mild symptoms, if at all, Zika infection during pregnancy can cause severe birth defects, including microcephaly. From January 2016 to June 2017, it was estimated that around 2,667 live births in the United States had brain abnormalities and/or microcephaly potentially related to Zika virus. The Zika virus in Brazil The latest Zika virus outbreak began in Brazil in 2015 with cases peaking in the country in 2016. In 2016, there were almost 274 thousand cases of Zika virus in Brazil. However, cases decreased significantly in 2017. In 2023, Brazil reported around 35 thousand Zika virus cases. Although the entire country has been impacted by the virus, certain areas have been affected more than others. In 2017, the Central-West of the country reported the most cases, but from 2019 to 2022 the Northeast saw the highest number of cases. Reported cases of microcephaly also peaked in 2016 with 2,276 such cases. By 2023, this number had dropped to just 318.

In 2024, approximately ****** Zika virus infections were reported in Latin America and the Caribbean, up from ****** cases reported a year earlier. This represents an overall decrease after peaking at over ******* infections in 2016. Brazil was by far the country with the highest number of Zika infections in Latin America as of 2024. Tropical diseases in Latin America Tropical diseases are illnesses prevalent in tropical and subtropical climates, where humidity and high temperatures are widespread. In 2024, there were approximately ******* cases of Chikungunya and in the beggining of 2025, over ****million cases of dengue in Latin America, with Brazil accounting for the highest number. With more than ******* infections, Brazil recorded the highest number of suspected and confirmed cases of malaria in the region in 2023. Zika virus in Brazil Brazil recorded over ****** cases of Zika virus infections in 2024. With around ******* cases, 2016 had the highest number of Zika infections in the country during the period between 2015 and 2024. In 2022, over ** percent of the Zika cases in Brazil occurred in Rio Grande do Norte, a state located in the northeast. With more than *** affected children as of 2021, the state of Pernambuco had the greatest number of verified cases of congenital Zika virus syndrome (CZS). CZS refers to a range of birth defects caused by Zika infection during pregnancy.

In 2023, Brazil reported around ****** cases of Zika virus disease, up from around ****** infections registered a year earlier. During the period analyzed, 2016 was the year with the most Zika infections in the South American country, with nearly ******* cases. Brazil is the most affected country in Latin America The Zika virus disease is mosquito borne and transmitted mainly through the bites of the Aedes aegypti, a mosquito also associated with dengue. Symptoms are often mild and include fever, headache, rashes, and joint pain. However, a Zika infection during pregnancy can cause certain congenital disorders. Between 2021 and 2023, Zika infections nearly doubled in Latin America, with Brazil reporting the highest number of Zika cases, followed by Bolivia and Belize in 2023. As of 2022, the most affected Brazilian region was the Northeast, where the majority of probable Zika cases were recorded. Zika testing market value worldwide As there is still no specific cure, vaccine, or treatment for Zika infections, preventing mosquito bites and safe sexual practices protect against this infection. Moreover, testing for Zika is recommended when symptoms appear after traveling to countries where the disease is still prevalent. Globally, the value of the Zika virus testing market has been increasing since 2020 and is expected to reach over *** million U.S. dollars by 2026.

NNDSS - TABLE 1PP. Viral hemorrhagic fevers, Sabia virus to Zika virus disease, non-congenital – 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. Notes: • These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. • Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html. • The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance. Footnotes: *Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks.

BackgroundOver 400,000 people across the Americas are thought to have been infected with Zika virus as a consequence of the 2015–2016 Latin American outbreak. Official government-led case count data in Latin America are typically delayed by several weeks, making it difficult to track the disease in a timely manner. Thus, timely disease tracking systems are needed to design and assess interventions to mitigate disease transmission.Methodology/Principal FindingsWe combined information from Zika-related Google searches, Twitter microblogs, and the HealthMap digital surveillance system with historical Zika suspected case counts to track and predict estimates of suspected weekly Zika cases during the 2015–2016 Latin American outbreak, up to three weeks ahead of the publication of official case data. We evaluated the predictive power of these data and used a dynamic multivariable approach to retrospectively produce predictions of weekly suspected cases for five countries: Colombia, El Salvador, Honduras, Venezuela, and Martinique. Models that combined Google (and Twitter data where available) with autoregressive information showed the best out-of-sample predictive accuracy for 1-week ahead predictions, whereas models that used only Google and Twitter typically performed best for 2- and 3-week ahead predictions.SignificanceGiven the significant delay in the release of official government-reported Zika case counts, we show that these Internet-based data streams can be used as timely and complementary ways to assess the dynamics of the outbreak.

NNDSS - TABLE 1PP. Yellow fever to Zika virus disease, non-congenital - 2019. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. Note: This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. Footnotes: U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published — CDC does not have data because of changes in how conditions are categorized. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks. * Case counts for reporting years 2018 and 2019 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the US, a US territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-US Residents' category. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. † Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).

This graph shows the number of Zika virus disease cases by U.S. state or territory in 2016. In that year, Florida reported ***** symptomatic Zika virus disease cases. Although cases of the Zika virus had been on the rise since 2015, malaria still remained the most serious of the mosquito-borne diseases for at-risk populations worldwide.

BackgroundIn 2015, high rates of microcephaly were reported in Northeast Brazil following the first South American Zika virus (ZIKV) outbreak. Reported microcephaly rates in other Zika-affected areas were significantly lower, suggesting alternate causes or the involvement of arboviral cofactors in exacerbating microcephaly rates.Methods and findingsWe merged data from multiple national reporting databases in Brazil to estimate exposure to 9 known or hypothesized causes of microcephaly for every pregnancy nationwide since the beginning of the ZIKV outbreak; this generated between 3.6 and 5.4 million cases (depending on analysis) over the time period 1 January 2015–23 May 2017. The association between ZIKV and microcephaly was statistically tested against models with alternative causes or with effect modifiers. We found no evidence for alternative non-ZIKV causes of the 2015–2017 microcephaly outbreak, nor that concurrent exposure to arbovirus infection or vaccination modified risk. We estimate an absolute risk of microcephaly of 40.8 (95% CI 34.2–49.3) per 10,000 births and a relative risk of 16.8 (95% CI 3.2–369.1) given ZIKV infection in the first or second trimester of pregnancy; however, because ZIKV infection rates were highly variable, most pregnant women in Brazil during the ZIKV outbreak will have been subject to lower risk levels. Statistically significant associations of ZIKV with other birth defects were also detected, but at lower relative risks than that of microcephaly (relative risk < 1.5). Our analysis was limited by missing data prior to the establishment of nationwide ZIKV surveillance, and its findings may be affected by unmeasured confounding causes of microcephaly not available in routinely collected surveillance data.ConclusionsThis study strengthens the evidence that congenital ZIKV infection, particularly in the first 2 trimesters of pregnancy, is associated with microcephaly and less frequently with other birth defects. The finding of no alternative causes for geographic differences in microcephaly rate leads us to hypothesize that the Northeast region was disproportionately affected by this Zika outbreak, with 94% of an estimated 8.5 million total cases occurring in this region, suggesting a need for seroprevalence surveys to determine the underlying reason.

BackgroundAs Zika virus continues to spread, decisions regarding resource allocations to control the outbreak underscore the need for a tool to weigh policies according to their cost and the health burden they could avert. For example, to combat the current Zika outbreak the US President requested the allocation of $1.8 billion from Congress in February 2016.Methodology/Principal FindingsIllustrated through an interactive tool, we evaluated how the number of Zika cases averted, the period during pregnancy in which Zika infection poses a risk of microcephaly, and probabilities of microcephaly and Guillain-Barré Syndrome (GBS) impact the cost at which an intervention is cost-effective. From Northeast Brazilian microcephaly incidence data, we estimated the probability of microcephaly in infants born to Zika-infected women (0.49% to 2.10%). We also estimated the probability of GBS arising from Zika infections in Brazil (0.02% to 0.06%) and Colombia (0.08%). We calculated that each microcephaly and GBS case incurs the loss of 29.95 DALYs and 1.25 DALYs per case, as well as direct medical costs for Latin America and the Caribbean of $91,102 and $28,818, respectively. We demonstrated the utility of our cost-effectiveness tool with examples evaluating funding commitments by Costa Rica and Brazil, the US presidential proposal, and the novel approach of genetically modified mosquitoes. Our analyses indicate that the commitments and the proposal are likely to be cost-effective, whereas the cost-effectiveness of genetically modified mosquitoes depends on the country of implementation.Conclusions/SignificanceCurrent estimates from our tool suggest that the health burden from microcephaly and GBS warrants substantial expenditures focused on Zika virus control. Our results justify the funding committed in Costa Rica and Brazil and many aspects of the budget outlined in the US president’s proposal. As data continue to be collected, new parameter estimates can be customized in real-time within our user-friendly tool to provide updated estimates on cost-effectiveness of interventions and inform policy decisions in country-specific settings.

NNDSS - Table I. infrequently reported notifiable diseases - 2017. In this Table, provisional cases of selected infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) are displayed.

Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting.

Case counts in these tables are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available.

Footnote: —: No reported cases. N: Not reportable. NA: Not available. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts.

• Case counts for reporting year 2017 are provisional and subject to change. Data for years 2012 through 2016 are finalized. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf.

† This table does not include cases from the U.S. territories. Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions.

§ Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. Additional information is available at http://wwwn.cdc.gov/nndss/document/5yearweeklyaverage.pdf.

¶ Updated weekly reports from the Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II.

** Not reportable in all jurisdictions. Data from states where the condition is not reportable are excluded from this table, except for the arboviral diseases and influenza-associated pediatric mortality. Reporting exceptions are available at http://wwwn.cdc.gov/nndss/downloads.html.

†† Data for Haemophilus influenzae (all ages, all serotypes) are available in Table II.

§§ In 2016, the nationally notifiable condition ‘Hepatitis B Perinatal Infection’ was renamed to ‘Perinatal Hepatitis B Virus Infection’ and reflects updates in the 2016 CSTE position statement for Perinatal Hepatitis B Virus Infection.

¶¶ Please refer to the MMWR publication for weekly updates to the footnote for this condition.

*** Please refer to the MMWR publication for weekly updates to the footnote for this condition.

††† Data for meningococcal disease (all serogroups) are available in Table II.

§§§ Novel influenza A virus infections are human infections with influenza A viruses that are different from currently circulating human seasonal influenza viruses. With the exception of one avian lineage influenza A (H7N2) virus, all novel influenza A virus infections reported to CDC since 2011 have been variant influenza viruses. Total case counts are provided by the Influenza Division, National Center for Immunization and Respiratory Diseases (NCIRD).

¶¶¶ Updated weekly from reports to the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.

**** Prior to 2015, CDC's National Notifiable Diseases Surveillance System (NNDSS) did not receive electronic data about incident cases of specific viral hemorrhagic fevers; instead data were collected in aggregate as "viral hemorrhagic fevers". Beginning in 2015, NNDSS has been updated to receive data for each of

Snapshot img

Zika Virus Therapeutics Market Size 2024-2028

The zika virus therapeutics market size is forecast to increase by USD 4.17 billion at a CAGR of 4.5% between 2023 and 2028.

The market is experiencing significant growth due to several key factors. One of the primary drivers is the availability of serology kits for the qualitative diagnosis of Zika virus infection. This allows for early detection and treatment of the disease, which is crucial given the asymptomatic nature of the infection in many cases. Additionally, increasing efforts by both government and private organizations to facilitate vaccine development are contributing to market growth. The lack of effective treatments and vaccines for Zika virus infection presents a significant challenge, but ongoing research and development efforts are expected to lead to new therapeutic options in the near future. Overall, the market is poised for substantial growth In the coming years as the global community continues to grapple with this emerging infectious disease.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The market represents a significant response to the global health concern posed by the Zika virus, primarily transmitted by Aedes mosquitoes. The virus is associated with severe birth defects, including microcephaly, and can also be contracted through sexual contact from an infected partner. The clinical manifestations of Zika virus infection include rash, malaise, headache, low-grade fever, and arthralgia. As of now, there are no approved vaccines or specific antiviral drugs for treating Zika virus infections.
These efforts include the development of small molecule inhibitors and other therapeutic approaches. The Zika virus market is expected to grow substantially due to the ongoing epidemic and the high unmet medical need for effective treatments. Additionally, the potential cross-reactive applications of Zika virus therapeutics in other mosquito-borne diseases, such as dengue, malaria, typhoid, and pneumonia, further expand the market's scope.

How is this Zika Virus Therapeutics Industry segmented and which is the largest segment?

The zika virus therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Product

  Acetaminophen
  Other NSAIDs


Geography

  North America

    Canada
    US


  Europe

    Denmark


  Asia

    China
    India


  Rest of World (ROW)

By Product Insights

The acetaminophen segment is estimated to witness significant growth during the forecast period.

Zika virus, a mosquito-borne infection from the Flavivirus family, is linked to severe birth defects, primarily microcephaly and congenital disabilities. The primary mode of transmission is through the bite of Aedes mosquitoes, but sexual contact can also spread the virus to the mother and fetus. Acetaminophen, a common analgesic and antipyretic, is used for symptomatic relief of fever, rash, malaise, headache, arthralgia, and pruritic maculopapular rashes. As a first-line therapy for pain conditions, acetaminophen is the most widely used medication. Its antipyretic effect helps reduce fever associated with Zika virus infection. However, potential treatments for Zika virus infection go beyond symptomatic relief.

Researchers are exploring small molecule inhibitors, such as Emricasan, which exhibits antiviral activity against Zika virus in laboratory studies by inhibiting host protein caspase-8 and blocking viral replication. Drug development processes involve safety and efficacy clinical trials for potential treatment options, addressing viral resistance development, broader efficacy, and safety profile. Novel drug targets and therapeutic approaches are being investigated, along with repurposing existing drugs. Market segmentation includes oral, injection, antiviral medications, vaccines, and medical diagnostic testing for severe cases. Driving factors include public health concerns, neurological complications, and commercial opportunities. Reimbursement policies and advances in technology, such as computational modeling and genomic analysis, are also crucial aspects of the market.

Get a glance at the Zika Virus Therapeutics Industry report of share of various segments Request Free Sample

The acetaminophen segment was valued at USD 8.2 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

Asia is estimated to contribute 35% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

The market

Analysis of ‘NNDSS - TABLE 1PP. Yellow fever to Zika virus disease, non-congenital’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from https://catalog.data.gov/dataset/c95cc113-1022-4dd1-b2b9-c7d96894348e on 26 January 2022.

--- Dataset description provided by original source is as follows ---

NNDSS - TABLE 1PP. Yellow fever to Zika virus disease, non-congenital - 2019. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Note: This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html.

Footnotes: U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published — CDC does not have data because of changes in how conditions are categorized. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks. * Case counts for reporting years 2018 and 2019 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the US, a US territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-US Residents' category. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. † Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).

--- Original source retains full ownership of the source dataset ---

Zika Virus Market Outlook

The Zika Virus market size was valued at approximately USD 1.2 billion in 2023 and is expected to reach around USD 2.6 billion by 2032, growing at a CAGR of 8.5%. The market growth is primarily driven by increasing awareness, rising incidence of mosquito-borne diseases, and advancements in diagnostic technologies. The continuous efforts in research and development for vaccines and therapeutics are further contributing to market expansion.

One of the primary growth factors for the Zika Virus market is the rising incidence of mosquito-borne diseases globally. The tropical and subtropical regions, which are breeding grounds for mosquitoes, have been witnessing significant outbreaks, leading to increased demand for effective prevention and treatment options. Additionally, the global travel boom has facilitated the spread of the virus to non-endemic areas, which has heightened the need for robust diagnostic and therapeutic measures.

The growing awareness about Zika Virus and its complications, particularly in pregnant women, has fueled the demand for diagnostic tests and vaccines. The severe birth defects caused by the virus, such as microcephaly, have led to significant public health campaigns and initiatives aimed at controlling the spread of the virus. This heightened awareness has resulted in increased funding and support from governmental and non-governmental organizations for research and development in this field.

Technological advancements in diagnostic testing have also played a crucial role in the growth of the Zika Virus market. The development of rapid and accurate diagnostic tests has enabled early detection and timely intervention, which is critical in controlling the spread of the virus. Furthermore, the advent of innovative vaccine technologies has accelerated the development of effective prophylactic measures against Zika Virus, contributing to market growth.

In the broader context of mosquito-borne diseases, Yellow Fever Vaccines have been a critical component in controlling outbreaks of yellow fever, a disease that shares transmission vectors with Zika Virus. The development and deployment of these vaccines have provided valuable insights into the challenges and strategies involved in vaccine distribution and public health campaigns. Lessons learned from yellow fever vaccination programs can be instrumental in shaping effective strategies for Zika Virus vaccine rollouts, particularly in regions where both diseases pose significant public health threats. The historical success of Yellow Fever Vaccines underscores the importance of sustained investment in vaccine research and development, which is crucial for addressing emerging viral threats like Zika Virus.

Regionally, Latin America remains one of the most affected areas by the Zika Virus, with countries like Brazil experiencing significant outbreaks. This has led to an increased focus on public health measures and investments in healthcare infrastructure in the region. Additionally, North America and Europe have also seen growing cases, primarily due to international travel, which has spurred demand for diagnostic tests and vaccines. The Asia Pacific region, with its dense population and tropical climate, is also a significant market for Zika Virus diagnostics and therapeutics.

Product Type Analysis

The Zika Virus market is segmented by product type into vaccines, diagnostic tests, and therapeutics. Each of these segments plays a critical role in managing and controlling the spread of the virus. Vaccines, although still in the developmental stages, hold significant promise for long-term prevention and control. The ongoing research and clinical trials are expected to bring effective vaccines to the market, which will drive substantial growth in this segment.

Diagnostic tests form a crucial segment in the Zika Virus market. The need for rapid, accurate, and cost-effective diagnostic solutions has led to the development of various innovative testing methodologies. These include RT-PCR tests, serological tests, and novel point-of-care diagnostics that can provide quick results, enabling timely medical interventions. The increasing adoption of these advanced diagnostic tests in hospitals, clinics, and research institutes is expected to drive the growth of this segment.

Therapeutics for Zika Virus are primarily focused on symptomatic relief, as no specific antiviral treat

Zika Virus Therapeutic Market Outlook

The global Zika virus therapeutic market size was valued at approximately $XX billion in 2023 and is projected to reach $XX billion by 2032, growing at a CAGR of XX% during the forecast period. The growth of this market is driven primarily by increased incidences of Zika virus infections, advancements in therapeutic research, and heightened awareness among populations in affected regions. These factors collectively contribute to the burgeoning need for effective treatments, thereby propelling the market forward.

One of the primary growth factors for the Zika virus therapeutic market is the rising prevalence of Zika virus infections across various regions, particularly in tropical and subtropical climates. This increase in Zika virus cases has heightened the urgency for effective therapeutic solutions to manage and alleviate symptoms. Additionally, the growing incidences have prompted increased funding and research initiatives by governments and private institutions, further accelerating the development of novel treatments and boosting market growth.

Advancements in biomedical research are another significant driver in this market. Recent breakthroughs in antiviral therapies, immunotherapy, and vaccine development are paving the way for more effective and targeted treatments against the Zika virus. These innovations are not only improving patient outcomes but also expanding the market as more effective treatments become available. The advent of cutting-edge technologies such as CRISPR and monoclonal antibodies are also playing a pivotal role in ushering new therapeutic avenues, thereby fueling market expansion.

The growing awareness and public health initiatives focusing on Zika virus prevention and treatment are further bolstering the market. Public health campaigns, educational programs, and global partnerships aimed at combating the spread of the virus have led to increased vigilance and early detection. Such initiatives are crucial in enhancing the uptake of therapies, thereby contributing to market growth. The role of international health organizations like the World Health Organization (WHO) in coordinating global efforts cannot be overstated, as they bring crucial attention and resources to the fight against Zika.

Regionally, the market exhibits robust growth, particularly in the Asia Pacific and Latin America regions, which are significantly affected by the Zika virus. These regions have seen substantial investments in healthcare infrastructure and research and development activities aimed at combating viral infections. Such investments are expected to continue driving market growth. Additionally, regions like North America and Europe are experiencing moderate growth due to their advanced healthcare systems and proactive measures in handling viral outbreaks.

Drug Class Analysis

The Zika virus therapeutic market is segmented by drug class into Antivirals, NSAIDs, Corticosteroids, Immunoglobulins, and Others. Each of these classes represents distinct approaches to managing and treating Zika virus infections, playing a crucial role in the overall market dynamics. Antivirals are a cornerstone in this segment, designed specifically to inhibit the replication of the Zika virus within the host's body, thereby reducing the viral load and mitigating symptom severity. With ongoing research and clinical trials, the antiviral segment is anticipated to witness substantial growth, driven by the need for targeted treatments.

NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) constitute another significant segment within the Zika virus therapeutic market. These drugs are primarily used to alleviate fever, pain, and inflammation associated with Zika virus infections. Although NSAIDs do not specifically target the virus, they play a pivotal role in symptomatic relief, thereby improving the quality of life for patients. The widespread availability and relatively low cost of NSAIDs contribute to their extensive usage and steady market growth.

Corticosteroids are employed in managing severe inflammation and immune responses triggered by Zika virus infections. These drugs help in reducing the immune system's overactivity, which can sometimes cause more harm than the infection itself. The application of corticosteroids in Zika virus treatment is growing, especially in severe cases where inflammation needs to be controlled promptly. This segment is likely to expand as more clinical evidence supports the efficacy of corticosteroids in treating Zika virus complications.

Market Overview The global Zika virus testing market is poised for significant growth in the coming years. With a market size of around $XXX million in 2025, it is projected to grow at a CAGR of XX%, reaching a value of $XXX million by 2033. The rise in Zika virus cases, particularly in tropical and subtropical regions, is a key driver for the market's expansion. Additionally, advancements in testing technologies, such as real-time PCR and serological assays, have improved the accuracy and accessibility of Zika virus diagnosis. Market Segmentation and Competitive Landscape The Zika virus testing market is segmented based on application (diagnostic, blood screening, and research) and type (nucleic acid amplification testing, serologic testing, and molecular diagnostics). Major players in the market include Chembio, Quest Diagnostics, ARUP Laboratories, Luminex, Siemens, Abbott Molecular, Hologic, ELITech Molecular Diagnostics, EUROIMMUN US, Creative Diagnostics, Vela Diagnostics, InBios International, Primerdesign, and Altona Diagnostics. These companies are investing in research and development to enhance their testing capabilities and expand their product offerings. Geographically, the market is divided into North America, South America, Europe, the Middle East & Africa, and Asia Pacific. North America and Europe currently hold the largest market share due to the high prevalence of Zika virus and robust healthcare systems.

This repository contains the data of the study "The impact of news exposure on collective attention in the United States during the 2016 Zika epidemic".

Epidemiological data

The folder zika_USA_weekly_cases_2016.zip contains weekly ZIKV incidence counts reported by the US Centers for Disease Control and Prevention in 2016, by state. Data were extracted from reports made publicly available by the CDC at: https://zenodo.org/record/584136#.Xk07-RNKjOQ

Web news data

The file news_GDELT_data.csv.gz contains all news items extracted from the GDELT platform (https://www.gdeltproject.org/) matching TAX_DISEASE_ZIKA as a Theme, and United_States as a Location in the GDELT platform.

TV closed captions

The file zika_TV_mentions_dataframe.csv contains all the TV news items of 2016 matching the word ``Zika" in the TV News Archive https://archive.org/details/tv

Wikipedia pageview counts

Dataset 1: wikipedia_dataset1_zika_daily_pageview_usa.csv

Content of each line of the dataset: day, pageview_count

The dataset contains the daily number of pageview counts of 128 different Wikipedia pages related to the Zika virus (aggregated and summed to total) originated in the United States, from January 1st to December 31st, 2016.

Dataset 2: wikipedia_dataset2_zika_daily_pageview_bystate.zip

Content of each line of the dataset: day, pageview_count, state

The dataset contains the daily number of pageview counts of 128 different Wikipedia pages related to the Zika virus (aggregated and summed to total) originated in the United States, disaggregated by state, from January 1st to December 31st, 2016.

Dataset 3: wikipedia_dataset3_zika_pagecount_by_city.csv

Content of each line of the dataset: US_city, pageview_count_Zika,pageview_count_total

The dataset contains the total number of pageview counts of 128 different Wikipedia pages related to the Zika virus (pageview_count_Zika) originated in 788 cities (US_city) of the United States with a population larger than 40,000 in 2016.The dataset also contains the total number of pageview counts to all Wikipedia pages (all Wikipedia projects, pageview_count_total) originated in 788 cities (US_city) of the United States with a population larger than 40,000 in 2016."

In 2024, Mexico reported ** cases of the Zika virus disease, up from ** cases recorded a year earlier. During the period analyzed, 2016 was the year with the highest number of Zika infections in the North American country, with more than ***** cases. Within the Latin American and Caribbean region, Brazil was the country that accounted for most Zika cases that year. A vector borne disease Zika is an infectious disease transmitted by Aedes mosquitoes, which is also a vector of dengue fever. In Latin America, Zika reached nearly ******* infections in 2024, most of which were reported in Brazil. This disease can also be sexually transmitted and can be acquired through blood transfusions. Zika is associated with microcephaly in newborns and in rare cases with the Guillain Barré syndrome. Preventive measures Prevention strategies are essential to reduce the economic and social burden of mosquito-borne diseases such as the Zika virus infection. Preventive measures aim to control and reduce the mosquito population while raising awareness to avoid bites with repellents and the importance of safe sex practices to minimize the risks of infection.

Analysis of ‘NNDSS - Table I. infrequently reported notifiable diseases’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from https://catalog.data.gov/dataset/43845f21-ac1c-4cc6-9628-1420583bef36 on 26 January 2022.

--- Dataset description provided by original source is as follows ---

NNDSS - Table I. infrequently reported notifiable diseases - 2016. In this Table, provisional* cases of selected† infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) are displayed.
Note:

These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting.

Case counts in these tables are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available.

“Symbols and footnotes changed in week #4, please refer to the MMWR publication for the symbols/footnotes for weeks 1, 2, and 3”.

Footnote: -: No reported cases N: Not reportable NA: Not available NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. * Case counts for reporting year 2016 are provisional and subject to change. Data for years 2011 through 2015 are finalized. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. † This table does not include cases from the U.S. territories. Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions.
§ Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. Additional information is available at http://wwwn.cdc.gov/nndss/document/5yearweeklyaverage.pdf. ¶ Includes both neuroinvasive and nonneuroinvasive. Updated weekly reports from the Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II. ** Not reportable in all reporting jurisdictions. Data from states where the condition is not reportable are excluded from this table, except for the arboviral diseases and influenza-associated pediatric mortality. Reporting exceptions are available at http://wwwn.cdc.gov/nndss/downloads.html. †† Office of Management and Budget approval of the NNDSS Revision #0920-0728 on January 21, 2016, authorized CDC to receive data for these conditions. CDC is in the process of soliciting data for these conditions (except Zika virus, congenital infection). CDC and the U.S. states are still modifying the technical infrastructure needed to collect and transmit data for Zika virus congenital infections. §§ Jamestown Canyon virus and Lacrosse virus have replaced California serogroup diseases. ¶¶ Data for Haemophilus influenzae (all ages, all serotypes) are available in Table II. *** Please refer to the MMWR publication for weekly updates to the footnote for this condition.
††† Please refer to the MMWR publication for weekly updates to the footnote for this condition. §§§ Data for meningococcal disease (all serogroups) are available in Table II. ¶¶¶ Please refer to the MMWR publication for weekly updates to the footnote for this condition. **** Updated weekly from reports to the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. †††† Please refer to the MMWR publication for weekly updates to the footnote for this condition. §§§§ All cases reported have occurred in travelers returning from affected areas, with their sexual contacts, or infants infected in ute

--- Original source retains full ownership of the source dataset ---

BackgroundThe 2015-16 Zika virus pandemic originating in Latin America led to predictions of a catastrophic global spread of the disease. Since the current outbreak began in Brazil in May 2015 local transmission of Zika has been reported in over 60 countries and territories, with over 750 thousand confirmed and suspected cases. As a result of its range expansion attention has focused on possible modes of transmission, of which the arthropod vector-based disease spread cycle involving Aedes species is believed to be the most important. Additional causes of concern are the emerging new links between Zika disease and Guillain-Barre Syndrome (GBS), and a once rare congenital disease, microcephaly.Methodology/principal findingsLike dengue and chikungunya, the geographic establishment of Zika is thought to be limited by the occurrence of its principal vector mosquito species, Ae. aegypti and, possibly, Ae. albopictus. While Ae. albopictus populations are more widely established than those of Ae. aegypti, the relative competence of these species as a Zika vector is unknown. The analysis reported here presents a global risk model that considers the role of each vector species independently, and quantifies the potential spreading risk of Zika into new regions. Six scenarios are evaluated which vary in the weight assigned to Ae. albopictus as a possible spreading vector. The scenarios are bounded by the extreme assumptions that spread is driven by air travel and Ae. aegypti presence alone and spread driven equally by both species. For each scenario destination cities at highest risk of Zika outbreaks are prioritized, as are source cities in affected regions. Finally, intercontinental air travel routes that pose the highest risk for Zika spread are also ranked. The results are compared between scenarios.Conclusions/significanceResults from the analysis reveal that if Ae. aegypti is the only competent Zika vector, then risk is geographically limited; in North America mainly to Florida and Texas. However, if Ae. albopictus proves to be a competent vector of Zika, which does not yet appear to be the case, then there is risk of local establishment in all American regions including Canada and Chile, much of Western Europe, Australia, New Zealand, as well as South and East Asia, with a substantial increase in risk to Asia due to the more recent local establishment of Zika in Singapore.

The Zika virus testing market, valued at $119.4 million in 2025, is projected to experience steady growth, driven by increasing incidence rates in endemic regions and advancements in diagnostic technologies. The market's Compound Annual Growth Rate (CAGR) of 3.0% from 2025 to 2033 reflects a consistent demand for accurate and timely Zika virus detection. Key drivers include heightened public health concerns, improved diagnostic capabilities enabling faster and more accurate results (such as molecular tests offering higher sensitivity and specificity compared to serologic tests), and expanding healthcare infrastructure, particularly in developing nations where Zika transmission is prevalent. Market segmentation reveals that molecular tests hold a larger share than serologic tests due to their superior performance, while hospitals and diagnostic centers constitute major end-users, reflecting the importance of established healthcare settings for reliable testing. The geographic distribution shows North America, with its robust healthcare system and advanced diagnostic capabilities, currently holds the largest market share, followed by Europe and Asia-Pacific regions experiencing varying levels of Zika prevalence and healthcare infrastructure development. However, growth potential in emerging markets is substantial, driven by increasing awareness, improving healthcare access and government initiatives promoting disease surveillance. The restraining factors influencing market growth are primarily associated with the intermittent nature of Zika outbreaks and the relatively low prevalence in many regions compared to other infectious diseases. Cost considerations associated with advanced diagnostic technologies may also limit broader adoption in some regions. However, ongoing research and development efforts focusing on cost-effective and point-of-care testing solutions are expected to mitigate this restraint. Companies like Chembio, Quest Diagnostics, and Abbott Molecular are key players contributing to advancements in technology and market expansion. Competitive activity focuses on developing rapid, accurate, and affordable testing solutions to address the global health challenge posed by the Zika virus. Future growth is expected to be influenced by advancements in diagnostic technology, improved disease surveillance programs, and evolving public health policies concerning vector-borne disease control. The market will continue to adapt and evolve, driven by the constant need for reliable and accessible Zika virus detection capabilities.